Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02899962 · ClinicalTrials.gov registry record · Phase 3
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
A Phase 3 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 722
- Enrollment target
NCT02899962 is a Phase 3 study that has completed, run by LEO Pharma. The registered enrollment target is 722 participants.
The verdict
NCT02899962, a Phase 3 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 722 participants
- Enrollment target
Study Summary
A phase 3 trial comparing the efficacy and safety of LEO 90100 aerosol foam with the aerosol foam vehicle used twice weekly as long-term maintenance therapy in subjects with psoriasis vulgaris. A 12-month, international, multi-centre, randomised, vehicle controlled, double-blind, 2-arm, parallel group trial.
Interventions
- DRUG LEO 90100 aerosol foam
- DRUG LEO 90100 aerosol foam vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 722 participants |
| Start Date | 2017-02-15 |
| Est. Completion | 2019-06-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02899962
The ClinicalTrials.gov registry entry for NCT02899962 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 722 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LEO 90100 aerosol foam is the first listed.
NCT02899962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02899962 about?
NCT02899962 is a clinical study titled "LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris". A phase 3 trial comparing the efficacy and safety of LEO 90100 aerosol foam with the aerosol foam vehicle used twice weekly as long-term maintenance therapy in subjects with psoriasis vulgaris. A 12-month, international, multi-centre, randomised, vehicle controlled, double-blind, 2-arm, parallel gr...
What is the current status of trial NCT02899962?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 722 participants. The study started on 2017-02-15. Estimated completion is 2019-06-26.
What interventions are being tested in trial NCT02899962?
The interventions under investigation include: LEO 90100 aerosol foam (DRUG), LEO 90100 aerosol foam vehicle (DRUG).
Who is sponsoring clinical trial NCT02899962?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.